Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: Prospective multicentre study

British Medical Journal

Volumn 315, Issue 7117, 1997, Pages 1194-1199

  Egger, Matthias ^a,g   Hirschel, Bernard ^b   Francioli, Patrick ^c   Sudre, Philippe ^b   Wirz, Marc ^a   Flepp, Markus ^d   Rickenbach, Martin ^c   Malinverni, Raffaele ^a   Vernazza, Pietro ^e   Battegay, Manuel ^f  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF GENEVA   (Switzerland)

^c UNIVERSITY OF LAUSANNE   (Switzerland)

^d UNIVERSITY OF ZURICH   (Switzerland)

^e CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^f UNIVERSITY OF BASEL   (Switzerland)

^g UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CLINICAL TRIAL; DISEASE COURSE; FEMALE; HETEROSEXUALITY; HOMOSEXUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ABUSE; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; SURVIVAL; SWITZERLAND;

EID: 9844238154     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.315.7117.1194     Document Type: Article

References (30)

1. Delta Coordinating Committee. Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Lancet 1996;348:283-91.
2. Saravolatz LD, Winslow DL, Collins G, Hodges JS, Pettinelli C, Stein DS, et al. Zidovudine alone or in combination with didanosine or zalcitabine in HIV-infected patients with the acquired immunodeficiency syndrome or fewer than 200 CD4 cells per cubic millimeter. N Engl J Med 1996;335:1099-106.
3. Hammer SM, Katzenstein DA, Hughes MD, Gundacker H, Schooley RT, Haubrich RH, et al. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. N Engl J Med 1996;335:1081-90.
4. CAESAR Coordinating Committee. Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: the CAESAR trial. Lancet 1997;349:1413-21.
5. Carpenter CCJ, Fischl MA, Hammer SM, Hirsch MS, Jacobson DM, Katzenstein DA, et al. Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. JAMA 1996;276:146-54.
6. Gulick RM, Mellor JW, Havlir D, Eron JJ, Gonzalez C, McMahon D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997;337:734-9.
7. Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, Currier JS, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. New Engl J Med 1997;337:725-33.
8. Cameron DW, Heath-Chiozzi M, Kravcik S, Mills R, Potthoff A, Henry D. Prolongation of life and prevention of AIDS complications in advanced HIV immunodeficiency with Ritonavir: update. In: 11th international conference an AIDS, Vancouver, 7-12 July 1996. Vancouver: 1996. (Abstract Mo B 411.)
9. BHIVA Guidelines Co-ordinating Committee. British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals. Lancet 1997;349:1086-92.
10. Carpenter CCJ, Fischl MA, Hammer SM, Hirsch MS, Jacobson DM, Katzenstein DA, et al. Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society - USA panel. JAMA 1997;277:1962-9.
11. Update: trends in AIDS incidence, deaths, and prevalence United States, 1996. MMWR 1997;46:165-73.
12. Mouton Y, Alfanderi S, Valette M, Cartier F, Dellamonica P, Humbert G, et al. Impact of protease inhibitors on AIDS defining events and hospitalizations in 10 French AIDS reference centres. AIDS 1997; 11:F101-5.
13. Rückläufige Aidsmeldungen - gibt es tatsächlich weniger Fälle? Bulletin des Bundesamt für Gesundheitswesen 1997; Jan 27:10-2.
14. Whitmore-Overton SE, Tillet HE, Evans BG, Allardice GM. Improved survival from diagnosis of AIDS in adult cases in the United Kingdom and bias due to reporting delays. AIDS 1993;7:415-20.
15. Ledergerber B, von Overbeck J, Egger M, Lüthy R. The Swiss HIV cohort study: rationale, organization and selected baseline characteristics. Soz Präventivmed 1994;39:387-94.
16. Von Overbeck J, Egger M, Davey Smith G, Schoep M, Ledergerber B, Furrer H, et al. Survival in HIV infection: do sex and category of transmission matter? AIDS 1994;8:1307-13.
17. Centers for Disease Control. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR 1992;41:1-20.
18. Cox DR. Regression models and life tables. J R Stat Soc 1972;34:187-220.
19. Tibshirani R, A plain man's guide to the proportional hazards model. Clin Invest Med 1987;5:63-8.
20. Glesby MJ, Hoover DR. Survivor treatment selection bias in observational studies: examples from the AIDS literature. Ann Intern Med 1996; 124:999-1005.
21. Perneger TV, Sudre P, Lundgren JD, Hirschel B. Does the onset tuberculosis in AIDS predict shorter survival? Results of a cohort study in 17 European countries over 13 years. AIDS in Europe Study Group. BMJ 1996;311:1468-71.
22. Staszewski S, Hill AM, Bartlett J, Eron JJ, Katlama C, Johnson J, et al. Reductions in HIV-1 disease progression for zidovudine/lamivudine relative to control treatments: a meta-analysis of controlled trials. AIDS 1997;11:477-83.
23. Lundgren JD, Phillips AN, Pedersen C, Clumeck N, Gatell JM, Johnson AM, et al. Comparison of long-term prognosis of patients with AIDS treated and not treated with zidovudine. JAMA 1994;271:1088-92.
24. Dorrucci M, Pezzotti P, Phillips AN, Alliegro MB, Rezza G, and the Italian Seroconversion Study. Antiretroviral treatment and progression to AIDS in HIV seroconverters from different risk groups. AIDS 1997;11:461-7.
25. Feinstein A. The role of observational studies in the evaluation of therapy. Stat Med 1984;3:341-5.
26. Fleming TR, Demets DL. Surrogate end points in clinical trials: are we being misled? Ann Intern Med 1996;125:605-13.
27. Concorde Coordinating Committe. Concorde: MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection. Lancet 1994;343:871-81.
28. Brun-Vézinet F, Boucher C, Loveday C, Descamps D, Fauveau V, Izopet J, et al. HIV-1 viral load, phenotype, and resistance in a subset of drug-naive participants from the Delta trial. Lancet 1997;350:983-90.
29. Babiker A. Can HIV viral load be used as a surrogate for clinical endpoints in HIV disease? In: 6th European conference on clinical aspects and treatment of HIV infection, Hamburg, 11-15 October 1997. Hamburg: 1997. (Abstract 103.)
30. Feinberg M. Hidden dangers of incompletely suppressive antiretroviral therapy. Lancet 1997;349:1408-9.